David Moody, Jr. recipient of the 2014 Nexus Award for Lifetime Achievement
ARLINGTON, Va. – The Center for Healthcare Supply Chain Research, HDMA’s nonprofit research foundation, and Genentech on Tuesday presented the 2014 Nexus Award for Lifetime Achievement to David Moody, Jr., CEO of Mutual Wholesale Drug Co.
Presented at the HDMA 2014 Business and Leadership Conference in Phoenix, the Nexus Award is the distribution industry’s highest individual honor, recognizing exceptional character, accomplishments and leadership in HDMA, the industry and community.
“As an independent pharmacist, leader, advocate and educator, Dave has made an indelible mark on his community, the distribution industry and the supply chain,” said Karen Ribler, EVP and COO of the Center for Healthcare Supply Chain Research. “We are pleased to recognize his achievements and welcome him into the prestigious Nexus winner’s circle.”
Moody’s career began during high school at Crabtree Pharmacy, an independent pharmacy located in his hometown of Durham, N.C. He continued to work at Crabtree through school at the University of North Carolina School of Pharmacy. Following his graduation in 1973, Moody became a pharmacist at the store, and later owned the pharmacy from 1981 until 1988.
Joining Mutual Drug in 1988, Moody developed an innovative generics program (C.A.P.S.), which provides affordable medications to independent pharmacies and their customers. He also established a government affairs program, overseeing advocacy efforts for Mutual Drug members on both the state and federal level.
Beyond Mutual Drug, Moody devotes his time to educating future pharmacists by serving as a preceptor for Appalachian College of Pharmacy, the Campbell University School of Pharmacy and Health Sciences, the Medical University of South Carolina and the UNC Eshelman School of Pharmacy. Moody received the 2006 Distinguished Service Award from the UNC-Chapel Hill Pharmacy Alumni Association. In 2010, he received an honorary Doctor of Pharmacy degree from the Campbell University College of Pharmacy and Health Sciences.
Moody has been an active member of HDMA, serving two terms as chairman of the association’s board of directors from 2010 to 2012. He also participates on several committees, including HDMA’s Executive and Federal Government Affairs committees.
“Dave truly embodies the spirit of the Nexus Award through his passion for his work and community,” said HDMA president and CEO John Gray. “It has been an honor to work with him, and we are grateful for his contributions to both HDMA and the entire distribution industry.”
Friendship Cottage Cheese announces new recipe ideas
FRIENDSHIP, N.Y. — Friendship cottage cheese on Tuesday announced a new collection of mix-in recipe ideas, which are ideal for even the most hectic schedules, the company said.
Friendship Mix-Ins present the following creations:
- Protein Packed, which includes high-protein nuts and seeds;
- Protein Power, which features a combination of dried apricots, crystallized ginger, hemp and pumpkin seeds;
- Maple Bacon, which features candied bacon bits, maple syrup and sea salt;
- Coconut Crunch is made with toasted coconut fkaes, cacao nibs and chopped cashews;
- Perfect Pearing features pears, toasted walnuts, mint and dried cranberries;
- Superfoods Trail Mix combines dried mango with mixed berries as well as toasted almonds, hemp and sesame seeds;
- Puttanesca features tomatoes, capers and olives drizzed with olive oil;
- Crunchy Kale includes spicy kale chips, chopped apples and toasted almonds; and
- Almond Delight features toasted almonds, shredded coconut, dark chocolate and caramel sauce.
The full-range of recipes can be found at grocery stores or at FriendshipDairies.com
Asana BioSciences acquires drug discovery platform from Endo Pharmaceuticals
BRIDGEWATER, N.J. — Asana BioSciences, a research and development company specializing in the discovery and development of new chemical and biological entities, on Tuesday announced that it has acquired an early stage branded pharmaceutical discovery platform from Endo Pharmaceuticals. Asana’s portfolio is comprised of multiple compounds for oncology and pain indications that are ready to enter clinical trials, the company said.
Asana is based in Bridgewater, N.J., and is led by Dr. Sandeep Gupta, CEO, who recently served as SVP of discovery and early development at Endo Pharmaceuticals.
“Asana’s mission is to develop novel and clinically differentiated products that address unmet clinical needs and provide new treatment options to physicians and patients," Gupta said. "Our team consists of highly experienced scientists who have successfully executed several drug discovery and clinical development projects. I am very excited about this portfolio and am looking forward to initiating our First-in-Man trials for our lead asset and moving other assets into clinical development.”
Asana is an independent member of the Amneal Alliance of Companies, which is made up of independent companies that focus on various disciplines within the life sciences. Other members include Amneal Pharmaceuticals, Therapeutic Proteins International, Kashiv Pharma and Prolong Pharmaceuticals.